Skip to content

Search for:

The Laboratory
Our Vision
Expertise
Products
International
Partners
Commitments
News
Contact

Search for:

The Laboratory
Our Vision
Expertise
Products
International
Partners
Commitments
News
Contact

The Laboratory
Our Vision
Expertise
Products
International
Partners
Commitments
News
Contact

Commercialisation of LORAZEPAM XILMAC® 4mg/ml, solution for injection, in France

Commercialisation of LORAZEPAM XILMAC® 4mg/ml, solution for injection, in France

Marketing letter - Lorazepam

edv2023-11-07T12:26:09+00:00November 6, 2023|

Actualités / News

Availability of XYLLOMAC® 1g, powder for solution for injection/IM-IV infusion, box of 1, in pharmacies 13/12/2023
Commercialisation of LORAZEPAM XILMAC® 4mg/ml, solution for injection, in France 06/11/2023
Availability of Ceplene® 0.5mg/0.5ml, solution for injection (Histamine dihydrochloride), in Germany and Austria 09/10/2023
Availability of Prostaphlin® 1000 mg for Czech market 26/01/2023
Commercialization of amoxicilline in Ireland 16/01/2023
THE LABORATOIRES DELBERT ANNOUNCES A SERVICES AGREEMENT WITH IBI 30/11/2022
Acquisition de TERALITHE® par les Laboratoires Delbert 05/07/2022
Acquisition of TERALITHE® by the Laboratoires Delbert 17/05/2022
Laboratoires Delbert – Help to Ukraine 14/04/2022
Augmentin® injectable devient Levmentin® : informations et dates de mise à disposition 07/03/2022

49, rue Rouelle
75015 Paris
France
Phone + 33 1 46 99 68 20

Download the company information sheet of Delbert Pharma

Terms & Conditions
Privacy Policy
Contact

All rights reserved to the Laboratoires Delbert© . RCS Paris 443 960 570 - SAS with capital of 217 928 €

French
English
Dutch
German

By continuing to browse, you accept the use of third-party services that may install cookiesOK No privacy policy